Truist analyst Jailendra Singh lowered the firm’s price target on Doximity (DOCS) to $52 from $58 and keeps a Hold rating on the shares. The company posted a mixed print with Q4 results ahead of consensus expectations, but FY26 guidance coming in below consensus, with the management attributing the prudent guidance approach to macro uncertainty and tough Y/Y comps, the analyst tells investors in a research note. Doximity has not yet seen the impact from recent macro uncertainty, though the management expects the pharma HCP digital market to grow at the lower end of 5%-7% market growth rate, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $60 from $65 at Mizuho
- Morning Movers: Charter to combine with Cox Communication
- Doximity price target lowered to $65 from $83 at Raymond James
- Doximity’s Strong Performance and Strategic Positioning Justify Buy Rating Despite Conservative Revenue Guidance
- Doximity price target lowered to $50 from $71 at Canaccord